BIEL + Viant + VLMS = $$$
Where Pain Relief Meets Partner Prosperity—And Ownership Is as Simple as a Share
BioElectronics Corporation (BIEL) is reshaping healthcare by fusing non-opioid pain therapy with a breakthrough equity model. Powered by publicly traded shares, BIEL offers its strategic partners—Viant Medical and VLMS Global Healthcare—not just influence, but financial upside tied directly to operational success.
And the best part? Partnership begins on the open market.
The Easiest Partnership in Healthcare
Forget complex deal structures, mergers, or joint ventures. The Smart Relief Alliance is designed for frictionless entry:
Acquire BIEL shares publicly—no barriers, no bureaucracy
Hold equity that grows with performance and traction
Retain autonomy while gaining strategic influence and capital upside
Ownership through execution. Influence through investment. It’s healthcare collaboration—simplified.
Global ActiPatch Adoption: Operational Impact That Drives Equity
BIEL’s flagship device, ActiPatch, is gaining real-world momentum across major healthcare markets, validating its effectiveness while boosting shareholder value.
Taiwan: Hospital Integration
ActiPatch is deployed at 14 leading hospitals, including NTU Hospital, Taipei Tzu Chi, Mackay Medical Center, and National Army Beitou.
Clinical adoption drives credibility and demand
Paves the way for insurance reimbursement
Fuels VLMS’s backend billing services and Viant’s hardware fulfillment
South Africa: Retail & Clinical Footprint
Distributed by Adcock Ingram, ActiPatch is available at pharmacies and platforms like Mopani, Cura Pharm, and Bizzmed35.
Enhances brand reach across chronic pain hotspots
VLMS captures coding volume in a 1-in-5 chronic pain population
Viant scales production to meet consumer demand
New Zealand: Direct-to-Consumer Rollout
Sold via ActiPatch.nz, distributed by TOP Medical NZ, targeting arthritis, fibromyalgia, and sports injuries.
Drug-free, OTC accessibility
VLMS taps into public reimbursement frameworks
Viant supports fulfillment logistics and device iteration
Every market penetration increases BIEL’s valuation—and with it, shareholder equity for its open-market investors.
Legislative Tailwinds: NOPAIN for Veterans Act
New bipartisan legislation could expand VA access to non-opioid therapies, including ActiPatch and RecoveryRx:
Formulary inclusion & prescribing access across VA facilities
Streamlined reimbursement for millions of veterans
Institutional validation of BIEL’s product portfolio
This isn’t just policy progress—it’s channel expansion that reinforces partner equity.
Partner Wealth Creation: Equity-Linked Execution
Viant and VLMS aren’t service providers—they’re value accelerators:
VLMS’s global reimbursement rollouts fuel BIEL’s share price
Viant’s scalable manufacturing triggers stock appreciation
Market growth (Taiwan, South Africa, New Zealand) delivers capital gains
Holding BIEL shares turns every operational milestone into personal financial upside.
Execution Is the Incentive
No special carve-outs. No preferential treatment. Just direct access to upside:
VLMS’s payer engagement becomes equity acceleration
Viant’s device deployment becomes portfolio growth
PPS climbs as markets adopt, and execution multiplies
A public platform where incentive and impact converge.
Influence Without Dilution
Owning BIEL stock grants:
Governance leverage through voting rights or board visibility
Liquidity access without restructuring
Strategic control without compromising autonomy
It’s smart ownership with clean mechanics—and compounding potential.
Strategic Synergy: Where Execution Builds Enterprise Value
Shareholding partners shape BIEL’s growth trajectory:
Collaborative commercialization strategies
Shared data ecosystems connecting clinical efficacy with backend infrastructure
Elevated investor trust via visible insider ownership
It’s a trust loop: performance → valuation → reinvestment → growth.
Public Status Accelerates Private Partner Success
Being public means more than transparency—it’s market magnetism:
Capital fuels Viant’s scale
Legitimacy enhances VLMS’s reimbursement networks
Visibility turns execution into investor confidence
BIEL’s public shell isn’t just a platform—it’s an engine of compounding value.
Final Thought: Join the Mission. Own the Outcome.
VLMS powers billing. Viant builds devices. BIEL delivers healing.
And with every step forward, the Smart Relief Alliance multiplies prosperity—for patients, investors, and partners alike.
✅ No red tape ✅ No restructuring ✅ Just open-market ownership and outsized opportunity
Welcome to Smart Relief Alliance 360—where healing pain fuels wealth creation, and becoming a partner is as simple as holding a share.
Where Pain Relief Meets Partner Prosperity—And Ownership Is as Simple as a Share
BioElectronics Corporation (BIEL) is reshaping healthcare by fusing non-opioid pain therapy with a breakthrough equity model. Powered by publicly traded shares, BIEL offers its strategic partners—Viant Medical and VLMS Global Healthcare—not just influence, but financial upside tied directly to operational success.
And the best part? Partnership begins on the open market.
The Easiest Partnership in Healthcare
Forget complex deal structures, mergers, or joint ventures. The Smart Relief Alliance is designed for frictionless entry:
Acquire BIEL shares publicly—no barriers, no bureaucracy
Hold equity that grows with performance and traction
Retain autonomy while gaining strategic influence and capital upside
Ownership through execution. Influence through investment. It’s healthcare collaboration—simplified.
Global ActiPatch Adoption: Operational Impact That Drives Equity
BIEL’s flagship device, ActiPatch, is gaining real-world momentum across major healthcare markets, validating its effectiveness while boosting shareholder value.
Taiwan: Hospital Integration
ActiPatch is deployed at 14 leading hospitals, including NTU Hospital, Taipei Tzu Chi, Mackay Medical Center, and National Army Beitou.
Clinical adoption drives credibility and demand
Paves the way for insurance reimbursement
Fuels VLMS’s backend billing services and Viant’s hardware fulfillment
South Africa: Retail & Clinical Footprint
Distributed by Adcock Ingram, ActiPatch is available at pharmacies and platforms like Mopani, Cura Pharm, and Bizzmed35.
Enhances brand reach across chronic pain hotspots
VLMS captures coding volume in a 1-in-5 chronic pain population
Viant scales production to meet consumer demand
New Zealand: Direct-to-Consumer Rollout
Sold via ActiPatch.nz, distributed by TOP Medical NZ, targeting arthritis, fibromyalgia, and sports injuries.
Drug-free, OTC accessibility
VLMS taps into public reimbursement frameworks
Viant supports fulfillment logistics and device iteration
Every market penetration increases BIEL’s valuation—and with it, shareholder equity for its open-market investors.
Legislative Tailwinds: NOPAIN for Veterans Act
New bipartisan legislation could expand VA access to non-opioid therapies, including ActiPatch and RecoveryRx:
Formulary inclusion & prescribing access across VA facilities
Streamlined reimbursement for millions of veterans
Institutional validation of BIEL’s product portfolio
This isn’t just policy progress—it’s channel expansion that reinforces partner equity.
Partner Wealth Creation: Equity-Linked Execution
Viant and VLMS aren’t service providers—they’re value accelerators:
VLMS’s global reimbursement rollouts fuel BIEL’s share price
Viant’s scalable manufacturing triggers stock appreciation
Market growth (Taiwan, South Africa, New Zealand) delivers capital gains
Holding BIEL shares turns every operational milestone into personal financial upside.
Execution Is the Incentive
No special carve-outs. No preferential treatment. Just direct access to upside:
VLMS’s payer engagement becomes equity acceleration
Viant’s device deployment becomes portfolio growth
PPS climbs as markets adopt, and execution multiplies
A public platform where incentive and impact converge.
Influence Without Dilution
Owning BIEL stock grants:
Governance leverage through voting rights or board visibility
Liquidity access without restructuring
Strategic control without compromising autonomy
It’s smart ownership with clean mechanics—and compounding potential.
Strategic Synergy: Where Execution Builds Enterprise Value
Shareholding partners shape BIEL’s growth trajectory:
Collaborative commercialization strategies
Shared data ecosystems connecting clinical efficacy with backend infrastructure
Elevated investor trust via visible insider ownership
It’s a trust loop: performance → valuation → reinvestment → growth.
Public Status Accelerates Private Partner Success
Being public means more than transparency—it’s market magnetism:
Capital fuels Viant’s scale
Legitimacy enhances VLMS’s reimbursement networks
Visibility turns execution into investor confidence
BIEL’s public shell isn’t just a platform—it’s an engine of compounding value.
Final Thought: Join the Mission. Own the Outcome.
VLMS powers billing. Viant builds devices. BIEL delivers healing.
And with every step forward, the Smart Relief Alliance multiplies prosperity—for patients, investors, and partners alike.
✅ No red tape ✅ No restructuring ✅ Just open-market ownership and outsized opportunity
Welcome to Smart Relief Alliance 360—where healing pain fuels wealth creation, and becoming a partner is as simple as holding a share.
1
